Prior Art for Invalidity: How to Uncover Killer References Against Asserted Patents
A practical framework for searching, evaluating and proving prior art in litigation, inter partes review and reexamination 1. Introduction When a patent is asserted against your company, finding the right prior art is often the most powerful defensive move. A strong reference can end a case early, drive a favorable settlement, or support a petition […]
Defending Against Patent Trolls
Using Invalidity Searches as Your Shield 1. Introduction Patent assertion by non-practising entities (NPEs), often called patent trolls or patent assertion entities, is a persistent business risk. These entities typically acquire patents, rarely make or sell products and generate revenue by demanding licence fees and by suing operating companies for infringement. Because litigation is expensive, […]
When Should You Conduct a Patent Invalidity Search?
A Strategic Timeline Introduction An invalidity search is a targeted hunt for prior art that could render one or more claims of a patent unpatentable, most often under 35 U.S.C. §§ 102 (novelty) and 103 (obviousness). It differs from a patentability search, which asks whether a new invention can be patented and from a freedom-to-operate […]
Patent Invalidity vs. Freedom to Operate
What’s the Difference? Introduction “Is this patent invalid?” and “Can we launch without infringing?” sound like cousins andare frequently confused. They are, in fact, different legal questions, answered with different evidence, at different times, for different decision-makers. Mixing them up can lead to wasted spend, false confidence or unnecessary abandonment of a product. This article […]
Leveraging Unconventional Invalidity Searches to Defeat Patent Litigation Claims
Finding prior art beyond patents and journals and turning it into admissible, persuasive invalidity evidence 1. Introduction When a company is sued for patent infringement, the most powerful defensive lever is often invalidity. A patent that should never have issued cannot be infringed. Yet issued patents carry a statutory presumption of validity and in district […]
Why Patent Invalidity Searches Are Critical to Your IP Portfolio
Testing the strength of patents before they are tested for you Introduction A patent is not a guarantee of exclusivity. It is a presumption. Once granted, a U.S. patent is presumed valid under 35 U.S.C. § 282, but that presumption can be overcome by evidence the examiner never saw. A patent invalidity search, also called […]
Accelerated Patent Invalidity Searches
Meeting Tight Court-Ordered Deadlines Introduction Patent litigation runs on schedules. Courts and specialized forums such as the U.S. International Trade Commission (ITC), set deadlines that leave defendants only weeks to identify prior art, analyze claims and commit to invalidity positions. When a defendant is served with a complaint, the clock starts for responsive pleadings, invalidity […]
Utility Model Invalidity: Cross-Border Prior Art Strategies Beyond US Patent Filings
How to find, prove and present prior art from outside the United States when challenging utility models Introduction The United States has no utility model system, so many US-trained practitioners are unfamiliar with how these rights are granted, enforced and attacked. Yet utility models (also called petty patents, short-term patents or innovation protections in some […]
Navigation and GPS Patent Invalidity: Military NAVSTAR Documents and Academic Prior Art
Locating, authenticating and using early GPS literature to challenge patent claims 1. Introduction The Global Positioning System (GPS) began as a U.S. military program called NAVSTAR (Navigation System with Timing and Ranging) and was developed across the 1970s and 1980s, declared operational in the mid-1990s and opened to civilian use long before that. Because so […]
mRNA Sequence Listing Requirements for Vaccine and Therapeutic Patents
Applying WIPO Standard ST.26 to modified, structured and multi-component RNA inventions 1. Introduction The success of mRNA vaccines and the growth of RNA therapeutics (protein-replacement mRNA, self-amplifying RNA, circular RNA, mRNA-encoded antibodies, in vivo gene editing payloads and cancer neoantigen vaccines) have made RNA sequences central to patent filings. In these filings, the sequence listing […]
